Jonathan P. DiNitto

Statistics

Publications

Citations

1.3K

H-Index

Active since

2003

Affiliations

Infinity Pharmaceuticals (United States)(Current)

Pfizer (United States)

University of Massachusetts Chan Medical School

Jonathan P. DiNitto is an author at Infinity Pharmaceuticals (United States) specializing in life sciences, molecular biology, and signal transduction.

Publications per year

2003–2017

Publications

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

K.S. Gajiwala, Joe C. Wu, James G. Christensen et al. · Proceedings of the National Academy of Sciences · 2009 · 386 citations · Full text

Medicine, Oncology, Pharmacology +16

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

David G. Winkler, Jonathan P. DiNitto, Janid A. Ali et al. · Chemistry & Biology · 2013 · 258 citations

Life Sciences, Immunology, Pathology +15

Structural Basis and Mechanism of Autoregulation in 3-Phosphoinositide-Dependent Grp1 Family Arf GTPase Exchange Factors

Jonathan P. DiNitto, Anna Delprato, Meng‐Tse Gabe Lee et al. · Molecular Cell · 2007 · 156 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +10

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

Catherine A. Evans, Tao Liu, André Lescarbeau et al. · ACS Medicinal Chemistry Letters · 2016 · 151 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Structural determinants of phosphoinositide selectivity in splice variants of Grp1 family PH domains

Thomas C. Cronin, Jonathan P. DiNitto, Michael Czech et al. · The EMBO Journal · 2004 · 108 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

1–5 of 12